Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L)

OBJECTIVE: To examine the efficacy and safety of adding the once-daily glucagon-like peptide-1 receptor agonist (GLP-1RA) lixisenatide to established basal insulin therapy alone or together with metformin, in people with type 2 diabetes and elevated glycated hemoglobin (HbA(1c)). RESEARCH DESIGN AND...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Riddle, Matthew C., Aronson, Ronnie, Home, Philip, Marre, Michel, Niemoeller, Elisabeth, Miossec, Patrick, Ping, Lin, Ye, Jenny, Rosenstock, Julio
Médium: Artigo
Jazyk:Inglês
Vydáno: American Diabetes Association 2013
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3747925/
https://ncbi.nlm.nih.gov/pubmed/23628617
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc12-2454
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky